The Glucosamine-Study - Full Text View

Purpose

Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability. Some indications exist for symptomatic and possible cartilage-structurmodifying effect on knee- and hip-osteoarthritis with glucosamine sulphate (GS). The OA process in the lumbar spine is most likely to OA processes in knees and hips, hence GS could have comparable symptomatic and structural effect on lumbar OA.

Study hypothesis: No difference in treatment effect exists between oral intake of GS- or placebo-capsules for patients` with chronic low back pain measured with Roland Morris Disability Questionnaire.

Condition	Intervention	Phase
Low Back Pain	Drug: Glucosamine sulphate	Phase IV

MedlinePlus related topics:

Back Pain

ChemIDplus related topics:

Glucosamine sulfate Glucosamine Glucosamine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings

Further study details as provided by Ullevaal University Hospital:

Primary Outcome Measures:

Roland Morris Disability Questionnaire

Secondary Outcome Measures:

Visual Analogue Scale
EuroQol-5D

Eligibility

Ages Eligible for Study:	25 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Low back pain for more than 6 months
Patient older than 25 years old
MRI findings comparable with lumbar degenerative/osteoarthritic changes.

Exclusion Criteria:

Spinal stenosis with neurological deficits
Spinal prolapse with neurological deficits
Rheumatoid arthritis, psoriatic arthritis,
Old lumbar fractures
Chronic pain syndromes (e.g. fibromyalgia)
Psychosocial status not suitable for participation
Pregnancy
Breastfeeding
Allergic to shellfish

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404079

Locations


Norway
	Ulleval Universtiy Hospital
	Oslo, Norway, 0450

Sponsors and Collaborators

Ullevaal University Hospital

Investigators


Principal Investigator:	Oliver Grundnes, MD	Ullevaal University Hospital

More Information

Study ID Numbers:	28130805
First Received:	November 23, 2006
Last Updated:	June 9, 2008
ClinicalTrials.gov Identifier:	NCT00404079
Health Authority:	Norway: Norwegian Medicines Agency

Keywords provided by Ullevaal University Hospital:

Chronic low back pain

Study placed in the following topic categories:

Neurologic Manifestations

Low Back Pain

Pain

Back Pain

Additional relevant MeSH terms:

Signs and Symptoms

Nervous System Diseases

ClinicalTrials.gov processed this record on July 03, 2008

Sponsored by:	Ullevaal University Hospital
Information provided by:	Ullevaal University Hospital
ClinicalTrials.gov Identifier:	NCT00404079